Details
Stereochemistry | RACEMIC |
Molecular Formula | C6H15NO2 |
Molecular Weight | 133.1888 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)CO
InChI
InChIKey=YKBZGEJJKPNRSI-UHFFFAOYSA-N
InChI=1S/C6H15NO2/c1-5(2)7-3-6(9)4-8/h5-9H,3-4H2,1-2H3
Molecular Formula | C6H15NO2 |
Molecular Weight | 133.1888 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2886569Curator's Comment: Description was created based on several sources, including
http://as7531.http.sasm3.net/dbget-bin/www_bget?D01958
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886569
Curator's Comment: Description was created based on several sources, including
http://as7531.http.sasm3.net/dbget-bin/www_bget?D01958
3-ISOPROPYLAMINO-1,2-PROPANEDIOL (Indenolol) is an antihypertensive agent, whose beta 1-adrenoceptor antagonist properties combined with beta 2-adrenoceptor agonist properties have been shown by experimental studies in animals. It was used for the treatment of angina pectoris, hypertension, arrhythmias
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: ATPase activity Sources: https://www.ncbi.nlm.nih.gov/pubmed/1356792 |
5.3 mM [IC50] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886569 |
|||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886569 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Indenolol Approved UseIndications: angina pectoris, hypertension, arrhythmias |
|||
Primary | Indenolol Approved UseIndications: angina pectoris, hypertension, arrhythmias |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886569
120 mg once daily orally
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1685314
Inhibitory effective range of 3-ISOPROPYLAMINO-1,2-PROPANEDIOL was 10-5000 uM for Na(+)- and K(+)-activated adenosine triphosphatase in guinea-pig heart preparations
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:29:05 GMT 2023
by
admin
on
Sat Dec 16 08:29:05 GMT 2023
|
Record UNII |
308N9VZ214
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
110857
Created by
admin on Sat Dec 16 08:29:05 GMT 2023 , Edited by admin on Sat Dec 16 08:29:05 GMT 2023
|
PRIMARY | |||
|
308N9VZ214
Created by
admin on Sat Dec 16 08:29:05 GMT 2023 , Edited by admin on Sat Dec 16 08:29:05 GMT 2023
|
PRIMARY | |||
|
6452-57-9
Created by
admin on Sat Dec 16 08:29:05 GMT 2023 , Edited by admin on Sat Dec 16 08:29:05 GMT 2023
|
PRIMARY | |||
|
229-255-8
Created by
admin on Sat Dec 16 08:29:05 GMT 2023 , Edited by admin on Sat Dec 16 08:29:05 GMT 2023
|
PRIMARY | |||
|
DTXSID60983148
Created by
admin on Sat Dec 16 08:29:05 GMT 2023 , Edited by admin on Sat Dec 16 08:29:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
any spot, apart from the principal spot, is not more intense than the spot in the chromatogram obtained with reference solution (a) (0.5 per cent) and at most 1 such spot is more intense than the spot in the chromatogram obtained with reference solution (b) (0.2 per cent)
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
any impurity: any spot, apart from the principal spot, is not more intense than the spot in the chromatogram obtained with the reference solution (0.2 per cent)
CHROMATOGRAPHIC PURITY (TLC)
USP
|